文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

PGT121 抗 HIV-1 广谱中和单抗的 1 期临床试验:安全性、药代动力学与抗病毒活性

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
PubMed 文献 · Nat Med · 2021-10-07

该研究包含随机双盲安慰剂对照剂量递增试验和多中心开放标签试验,评估 HIV-1 V3 聚糖特异性抗体 PGT121 单次给药的安全性、药代动力学和抗病毒活性。48 名参与者中未报告治疗相关严重不良事件,PGT121 使病毒血症者 HIV RNA 中位下降 1.77 log,2 例低基线病毒载量者实现≥168 天无 ART 病毒抑制。

要点

  • PGT121 单次给药在 3、10、30 mg/kg 剂量下安全耐受,未报告治疗相关严重不良事件。
  • 病毒血症者 HIV RNA 中位下降 1.77 log,病毒载量最低点中位 8.5 天。
  • 2 例低基线病毒载量者实现≥168 天无 ART 病毒抑制,反弹病毒对 PGT121 完全或部分敏感。

核心结论

  • PGT121 单次给药安全耐受,在病毒血症者中显示抗病毒活性,支持进一步研究抗体用于 HIV 长期抑制。

研究设计与样本

  • 单中心随机双盲剂量递增安慰剂对照试验,PGT121 3、10、30 mg/kg 单次给药于 HIV 未感染成人和 ART 抑制的 HIV 感染者。
  • 多中心开放标签试验,PGT121 30 mg/kg 单次输注于未接受 ART 的病毒血症 HIV 感染者。
  • 共纳入 48 名参与者,主要终点为安全性、耐受性、药代动力学和抗病毒活性。

主要发现

  • 48 名参与者中未报告治疗相关严重不良事件、潜在免疫介导疾病或 3 级及以上不良事件。
  • PGT121 受者最常见反应为静脉/注射部位压痛、疼痛和头痛。
  • HIV 感染者输注 PGT121 后绝对和相对 CD4+ T 细胞计数无变化,未产生中和性抗药抗体。
  • 病毒血症者血浆 HIV RNA 中位下降 1.77 log,病毒载量最低点中位 8.5 天。
  • 2 例低基线病毒载量者输注后实现≥168 天无 ART 病毒抑制,反弹病毒对 PGT121 完全或部分敏感。

关键数值与推荐

  • 主要终点为安全性、耐受性和病毒血症 HIV 感染者中的抗病毒活性。
  • 次要终点包括抗 PGT121 抗体滴度、CD4+ T 细胞计数变化及 PGT121 耐药相关 HIV-1 序列变异。

临床怎么用

  • PGT121 在 3–30 mg/kg 单次给药下安全耐受,支持在低病毒载量、未接受 ART 人群中进一步评估抗体治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg-1 in HIV-uninfected adults and HIV-infected adults on antiretroviral therapy (ART), as well as a multicenter, open-label trial of one infusion of PGT121 at 30 mg kg-1 in viremic HIV-infected adults not on ART (no. NCT02960581). The primary endpoints were safety and tolerability, pharmacokinetics (PK) and antiviral activity in viremic HIV-infected adults not on ART. The secondary endpoints were changes in anti-PGT121 antibody titers and CD4+ T-cell count, and development of HIV-1 sequence variations associated with PGT121 resistance. Among 48 participants enrolled, no treatment-related serious adverse events, potential immune-mediated diseases or Grade 3 or higher adverse events were reported. The most common reactions among PGT121 recipients were intravenous/injection site tenderness, pain and headache. Absolute and relative CD4+ T-cell counts did not change following PGT121 infusion in HIV-infected participants. Neutralizing anti-drug antibodies were not elicited. PGT121 reduced plasma HIV RNA levels by a median of 1.77 log in viremic participants, with a viral load nadir at a median of 8.5 days. Two individuals with low baseline viral loads experienced ART-free viral suppression for ≥168 days following antibody infusion, and rebound viruses in these individuals demonstrated full or partial PGT121 sensitivity. The trial met the prespecified endpoints. These data suggest that further investigation of the potential of antibody-based therapeutic strategies for long-term suppression of HIV is warranted, including in individuals off ART and with low viral load.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Stephenson KE, Julg B, Tan CS, et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021. PMID: 34621054. doi:10.1038/s41591-021-01509-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。